In a thought-provoking panel discussion, leading Chinese experts Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma tackled several pressing issues in prostate cancer care. The conversation spanned diagnostic dilemmas like PI-RADS 3 lesions, the promise and pitfalls of AI-assisted pathology, the strategic role of neoadjuvant therapy, and the sobering setbacks in mCRPC clinical trials. Their insights reflect both the progress and persistent challenges in the evolving landscape of prostate cancer management.
